Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded up 20.4% on Friday. The company traded as high as GBX 2.90 and last traded at GBX 2.90. Approximately 4,199,980 shares changed hands during trading, an increase of 67% from the average daily volume of 2,518,765 shares. The stock had previously closed at GBX 2.40.
ImmuPharma Stock Up 20.4%
The stock has a market cap of £18.10 million, a price-to-earnings ratio of -3.49 and a beta of 3.02. The business has a 50-day moving average of GBX 3.46 and a 200-day moving average of GBX 4.48.
ImmuPharma (LON:IMM – Get Free Report) last released its quarterly earnings data on Tuesday, September 15th. The company reported GBX (0.84) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 559.87%. Equities analysts anticipate that ImmuPharma plc will post -339.00 earnings per share for the current year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
